California Retina Consultants
California Retina Consultants was paid $11.81M by Medicaid between Jan 2018 and Nov 2024, across 22 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 33% of everything it billed.
33Billing provider infoCALIFORNIA RETINA CONSULTANTS
SANTA BARBARA, CA 93103
SANTA BARBARA, CA 93103
33aNPI1386737617assigned 09/30/2006
33bProvider typeSpecialist
28Total paid$11.81M
24GClaims79,463
24DCodes billed22
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#14 of 1,230
Median peer was paid$51K
This provider vs. median230×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,131 | $460K | |
| 2019 | 10,007 | $854K | |
| 2020 | 9,813 | $1.11M | |
| 2021 | 11,204 | $1.78M | |
| 2022 | 12,935 | $2.39M | |
| 2023 | 15,129 | $3.12M | |
| 2024incomplete | 11,244 | $2.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 33% | 18,907 | 14,788 | $3.91M |
| J0178 | Injection, aflibercept, 1 mg | 21% | 1,961 | 1,362 | $2.51M |
| J2778 | Injection, ranibizumab, 0.1 mg | 19% | 3,398 | 2,497 | $2.30M |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 11% | 1,871 | 1,155 | $1.28M |
| 92134 | 4.7% | 23,124 | 22,382 | $551K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 3.4% | 8,450 | 8,291 | $397K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 3.1% | 8,314 | 8,144 | $363K |
| J9035 | Injection, bevacizumab, 10 mg | 1.2% | 2,048 | 1,337 | $145K |
| 92226 | <1% | 5,142 | 3,060 | $112K | |
| 92250 | <1% | 2,718 | 2,656 | $97K | |
| 92235 | <1% | 731 | 717 | $62K | |
| J3490 | Unclassified drugs | <1% | 25 | 17 | $21K |
10 more codes
| 92202 | <1% | 1,456 | $16K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 241 | $11K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 141 | $8K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 95 | $7K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 163 | $7K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 117 | $6K |
| 92201 | <1% | 452 | $5K | |
| 92225 | <1% | 24 | $1K | |
| 76512 | <1% | 15 | $946.87 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 70 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEGROW, PAUL (C.O.O.)